Development of next-generation antibody drug conjugates for the treatment of lung cancer and multiple myeloma

• Research unit: INNOSUISSE
• Project number: 18533.1 PFLS-LS

Short description (German)

Development of next-generation antibody drug conjugates for the treatment of lung cancer and multiple myeloma

Short description (English)

Development of next-generation antibody drug conjugates for the treatment of lung cancer and multiple myeloma

Abstract (German)

NBE-Therapeutics has developed novel next-generation homogeneous antibody drug conjugates (ADCs)|with proven efficacy in preclinical models of solid tumors, like lung and breast cancer, and hematological|tumors, particularly in multiple myeloma. The goal of the project is to generate optimized ADC lead candidates from early candidates which will be guided by a rigorous assessment of the developability profiles of the ADCs. It will include the development of advanced analytical assays and will lead to novel and optimized ADC candidates for clinical development.

Abstract (English)

NBE-Therapeutics has developed novel next-generation homogeneous antibody drug conjugates (ADCs)|with proven efficacy in preclinical models of solid tumors, like lung and breast cancer, and hematological|tumors, particularly in multiple myeloma. The goal of the project is to generate optimized ADC lead candidates from early candidates which will be guided by a rigorous assessment of the developability profiles of the ADCs. It will include the development of advanced analytical assays and will lead to novel and optimized ADC candidates for clinical development.